Gerresheimer Ag · XETR:GXI
Gerresheimer — Investor Presentation (December 2021)
42 slides from Gerresheimer's investor presentation, December 2021
Slide 1: Investor Presentation
Investor Presentation Gerresheimer AG December 2021
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Gerresheimer at a Glance
Gerresheimer at a Glance gerresheimer
Slide 4: Our Vision: Innovating for a Better Life
Our Vision: Innovating for a Better Life Partner of Choice for Customers and Patients Worldwide Leading partner for the pharmaceutical, Innovative platforms and solutions for biotech and cosmetics industry customers and patients worldwide 4 December 21 Gerresheimer AG - Investor Presentation
Slide 5: Investment in Global Healthcare Mega Trends
Investment in Global Healthcare Mega Trends Investment Rational Transforming into a solution and platform provider – accompanying the customers alongside the whole value chain Anticipating global mega trends and investing into growth opportunities – entering new markets High Value Solutions as growt
Slide 6: One Gerresheimer: Broad and Unique Portfolio
One Gerresheimer: Broad and Unique Portfolio Three Segments for One Gerresheimer Gerresheimer Group Revenues 2020 Adj. EBITDA 2020 Leverage at 3.3x EUR 1.42 bn EUR 310 m as of August 31, 2021 Plastics & Devices Primary Packaging Glass Advanced Technologies (P&D) (PPG) (GAT) Revenue 2020 Adj. EBITDA
Slide 7: Regionally Present and Globally Connected
Regionally Present and Globally Connected Producing for the Customers at the Customers Strong Focus Strong Global Presence 3 Focus Sectors 37 plants in 15 countries and Sales in 91 countries across 6 continents 81% 13% 6% Pharma & Biotech Cosmetics Other Over 1,500 customers with relationships to ma
Slide 8: Overproportionate Growth with High Value Solutions
Overproportionate Growth with High Value Solutions Core Business: Pharma Revenue by Segment Pharma business growing 15% at high-single digit rate, 29% 24% with high-value solutions 31% by far out-performing 2025 2020 54% 47% High-value Solutions 1 Standard Packaging Contract-Manufactured Devices 1.
Slide 9: Outstanding Growth with Biologics Customers
Outstanding Growth with Biologics Customers Core Business: Pharma Proprietary Revenue by Customer Application Micropumps not included Pharma business growing 13% at high-single digit rate, 17% with Biologic Solutions by far out-performing 2020 2025 87% 83% Biologics Non-Biologics 9 December 21 Gerre
Slide 10: Focus – Transform – Grow
Focus — Transform — Grow gerresheimer
Slide 11: Healthcare is More Important Than Ever Before
Healthcare is More Important Than Ever Before We Anticipate Global Mega Trends Emerging Increase in Urban population Markets: chronic diseases and growing upper Increasing health and aging classes care access population More self- Increasing medication and Focus on importance of individual sustainab
Slide 12: Dedicated and Experienced Management Team
Dedicated and Experienced Management Team Since 2019 Complete Dr. Bernd Metzner Dietmar Siemssen Dr. Lukas Burkhardt since 2019 since 2018 since 2018 Chief Financial Officer Chief Executive Officer Board Member Plastics & Devices Primary Packaging Glass Advanced Technologies Management positions Man
Slide 13: Transforming Gerresheimer into a growth company as innovation leader
Transforming our Gerresheimer into a growth company as innovation leader and solution provider 201 5
Slide 14: Strong Vision: Developed for 2028
Strong Vision: Developed for 2028 Ambitious Goals in Five Strategic Directions Defined Vision 2028: Leading in Health and Well-Being Delivery Solutions 2019 16 December 21 Gerresheimer AG - Investor Presentation
Slide 15: Outperforming Markets and Accelerating Growth
Outperforming Markets and Accelerating Growth Gerresheimer Becomes More Successful Step by Step Mid to High Market Growth Segments Single Digit Next Level Organic − Innovative products, platforms and Growth solutions − Advanced − Increasing portfolio of high value products Technologies − Focus on in
Slide 16: Triple Sales With Biologic Customers
Triple Sales With Biologic Customers Growth Segments: Example Biologics Gx® Biological Solutions - cross divisional team Innovative product solutions for biotech drugs Best possible packaging configuration Interdisciplinary team of scientists, designers, engineers and product managers Full-service p
Slide 17: Working Today on Tomorrow's Earnings Potentials
Working Today on Tomorrow’s Earnings Potentials Continuously Enhancing our Portfolio Offering by Best Solutions and Platforms Gerresheimer is a Innovation as key growth driver growth company as innovation leader and solution provider Continue to innovate: own products with own IP Strategic partnersh
Slide 18: Digitalisation Offers new Business Opportunities
Digitalisation Offers new Business Opportunities Deep Dive Connected Devices & Smart Business Models Digital solutions enable Increase of therapy effectiveness Reduction of global healthcare costs Physician / Platform Disease Manager Service Disease and digital expertise enables Creation of digital
Slide 19: Serving our Global Customers
Serving our Global Customers Global Expansion: Increase Footprint and Market Penetration North America: South America: Europe: Asia: Increasing service Capacity expansion in New plant for medical New sales structure offering: plastics and cosmetics devices steadily and expansion of New plant for pla
Slide 20: Connect Competence Centers to a Global Network
Connect Competence Centers to a Global Network Groupwide Technology Centers We connect our technology centers Glass Innovation & Technical Competence Center Technical Competence Technology Center Syringes Center of Excellence & Center/Medical Systems Innovation Center Smart Devices Connecting expert
Slide 21: We are Seizing Unique Business Opportunities
We are Seizing Unique Business Opportunities Investing Into Value-enhancing Future Growth Investment Scenario during 2021 and 20221 Base Capex 4% Entrepreneurial Ventures: In order to benefit from Growth Capex 5% Capacity Extension for foreseeable market Injectables2 dynamics we are investing Accele
Slide 22: Digitalisation Offers new Business Opportunities
Digitalisation Offers new Business Opportunities Deep Dive Connected Devices & Smart Business Models Digital solutions enable Increase of therapy effectiveness Reduction of global healthcare costs Physician / Platform Disease Manager Service Disease and digital expertise enables Creation of digital
Slide 23: Rethink the Future: Growth Through Sustainability
Rethink the Future: Growth Through Sustainability Holistic Approach With Ambitious Targets Sets New Standards Sustainability Goals Already strong today: 25 December 21 Gerresheimer AG - Investor Presentation
Slide 24: Sustainability as Growth Driver
Sustainability as Growth Driver Ambitious Sustainability Goals for the Future GxPure GxCircular GxCare Engagement for climate and Engagement for resources through Engagement for people - for our environment sustainable products, responsible employees and our impact on supply chain and circular econo
Slide 25: Set Ambitious Targets and Achieve Them
Set Ambitious Targets and Achieve Them Growth Acceleration in the Mid-Term High-single digit Mid-single digit +3.5% CAGR + 2% 2022 2015 2019 2020 The transformation is ongoing 27 December 21 Gerresheimer AG - Investor Presentation
Slide 26: Q3 2021 Earnings Review
Q3 2021 Earnings Review gerresheimer
Slide 27: Successful on the Sustainable Growth Path
Successful on the Sustainable Growth Path Key Take-Aways Q3 2021 High Single Digit Growth: Boosting Sustain growth Org. revenue growth: High Value Solutions: momentum Adj. EBITDA margin: +9.8% core 1 ~ +30% yoy in the 20.9% core1 (FXN) +10.0% group fourth quarter – Adj. EPS: Biologics: +30% yoy +5.2
Slide 28: New Gerresheimer: Growth Along the Whole Portfolio
New Gerresheimer: Growth Along the Whole Portfolio Leveraging Growth With the Right Product Solutions High Value Solutions Global mega trends, e.g. biologics, Biological Solutions boosting growth of High Value Solutions Pharma Solutions/ Regional expansion balancing the global Underlying Business fo
Slide 29: Leverage Beauty Solutions With our Pharma Skills
Leverage Beauty Solutions With our Pharma Skills Deep Dive Beauty Solutions: Cosmetic Goes Health Examples for anticipating global beauty trends through pharma expertise Smart Injectables High Value Irradiated bottles & Pen systems Devices Pharma Glass “back” system HEALTHCARE Holistic approach Surg
Slide 30: Innovate on Solutions to Enlarge Beauty Portfolio
Innovate on Solutions to Enlarge Beauty Portfolio Cosmetics and Beauty Growth Opportunities in Tubular, Moulded and Plastics Beauty Solutions in Tubular Selective Segment Sustainability & Beauty − Newly developed pipettes as − Premium options offer − Gx positioned as leading holistic solution in a r
Slide 31: Q3 2021: Revenue Growth Accelerated
Q3 2021: Revenue Growth Accelerated Operational View on key KPIs Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) organic growth yoy 3.5% organic growth yoy organic growth 9.8% core business: 5.2% core business: yoy: Adj. EBITDA margin core 20.9% 382 (FXN): 75 75 0,97 0,97 349 381 1.01 7
Slide 32: Strong Positions Provide Pricing Power
Strong Positions Provide Pricing Power Q3 2021 Adj. EBITDA Margin Reconciliation in Gx Core Business (in %) +0.8 23.0 22.2 ~1.5 20.9 0.6 Q3 2021 Q3 Subsequent Q3 2021 Q3 2020 FX-neutral Quarters FX-neutral FX-neutral Pro-forma Pass-Through Effects Timing Effects − Direct pass-through of raw and − Q3
Slide 33: Strong Sales Performance in Core Business
Strong Sales Performance in Core Business Q3 2021: Divisional Performance and Highlights Organic yoy & margin In EUR m Revenues Adj. EBITDA Strong growth in the segment +8.0% -0.8% — Strong organic revenue growth supported by 208 pass-through of increasing raw material cost P&D 194 52 51 — Adj. EBIT
Slide 34: Reconciliation Q3 2021
Reconciliation Q3 2021 Reported and Adjusted Financials on Group Level Q3 2021 Q3 2020 Organic growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 382.0 382.0 349.2 10.0% EBITDA 69.1 5.7 74.8 75.0 2.1% Depreciation & -34.7 8.7 -26.0 -26.3 Amortization EBIT 34.4 14.4 48.8 48.
Slide 35: Good Free Cashflow Performance
Good Free Cashflow Performance Cash Flow and Financial Debt In EUR m Q3 2021 Q3 2020 Change Comments Adjusted EBITDA 74.8 75.0 -0.2 EUR ~ -1m negative FX effects Change in net working capital 23.9 4.7 19.2 Strong improvement of net working capital Net interest paid -2.0 -2.3 0.3 Net taxes paid -8.6
Slide 36: Profitable Growth Accelerating
Profitable Growth Accelerating Guidance Confirmed – Focus on Absolute Adj. EBITDA Targets For Core Business1 (FXN) FY 2021 Mid-term Accelerate Mid-single High-single Revenue growth digit growth digit growth Further expand ~ 22 to 23% ~ 23% Adj. EBITDA margin Drive Adj. EPS growth ≥ 10% ≥ 10% p.a. an
Slide 37: Market Environment
Market Environment gerresheimer
Slide 38: Underlying Market Growth
Underlying Market Growth Expected development of DDD (5-Year CAGRs in %) 2010 - 2016 - 2021 - 2015 2020 2025 − Slight global growth of DDDs Global 3,8 2,2 0,7 − Regional growth pattern sustains: Emerging regions to outperform developed markets Developed 0,9 1,1 -0,1 − Biological volumes should outpa
Slide 39: Adressing Attractive Niches
Adressing Attractive Niches CAGRs of Relevant Product Segments Drug Cosmetics Pharma Pharma Syringes Delivery Glass Glass1 Plastic Devices Estimated Market Size 2020² ~ 1.9 ~ 2.5 ~ 6.5 ~ 1.1 ~ 5.0 (in € bn) Market CAGR MID TO HIGH ‘20-’25² MID SINGLE DIGIT SINGLE DIGIT (in %) The strategic relevant
Slide 40: Appendix
Appendix 43 December 21 Gerresheimer AG - Investor Presentation
Slide 41: Financial Calendar
Financial Calendar Publication Financial Publication 1st Publication 2nd Publication 3rd Year 2021 Results Quarter Results 2022 Quarter Results 2022 Quarter Results 2022 February April July October 17, 2022 7, 2022 13, 2022 12, 2022 44 December 21 Gerresheimer AG - Investor Presentation
Slide 42: serresheimer
serresheimer innovating for a better life